---

原文標題：
Roche to invest USD 50 billion in pharmaceuticals and diagnostics in the
United States over the next five years
原文連結：https://tinyurl.com/2h8hnjuv
發布時間：Tue, April 22, 2025 at 1:00 PM GMT+8
記者署名：F. Hoffmann-La Roche Ltd
原文內容：

Basel, 22 April 2025 - Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that
 it will invest USD 50 billion into the United States of America in the next
five years. These investments further strengthen Roche’s already significant
US footprint with 13 manufacturing and 15 R&D sites across the Pharmaceutical
and Diagnostics Divisions, and are expected to create more than 12,000 new
jobs, including nearly 6,500 construction jobs,  as well as 1,000 jobs at new
and expanded facilities.

As part of this investment, Roche will increase its existing footprint of more
 than 25,000 employees in 24 sites across eight US states. The investment will
 include:

Expanded and upgraded US manufacturing and distribution capabilities for its
innovative medicines and diagnostics portfolio in Kentucky, Indiana, New
Jersey, Oregon and California

A state-of-the-art gene therapy manufacturing facility in Pennsylvania

A new 900,000 square foot manufacturing centre to support Roche’s expanding
portfolio of next generation weight loss medicines (location to be announced)

A new manufacturing facility for continuous glucose monitoring in Indiana

A new R&D centre in Massachusetts, conducting cutting-edge artificial
intelligence (AI) research and serving as hub for our new cardiovascular,
renal and metabolism research and development efforts

Significant expansion and upgrading of our existing pharmaceuticals and
diagnostics R&D centres in Arizona, Indiana and California

“Roche is a Swiss company with a strong heritage in more than 130 countries
globally. Today’s announced investments underscore our long-standing
commitment to research, development and manufacturing in the US,” said Thomas
 Schinecker, Roche Group CEO. “We are proud of our 110 year legacy in the
United States which has been a key driver for jobs, innovation and the
creation of intellectual property in the US, across both our Pharmaceutical
and Diagnostics Divisions. Our investments of USD 50 billion over the next
five years will lay the foundation for our next era of innovation and growth,
benefiting patients in the US and around the world.”

Once all new and expanded manufacturing capacity comes on-line, Roche will
export more medicines from the US than it imports. Today, its diagnostics
division already has an export surplus from the US to other countries.

About Roche
Founded in 1896 in Basel, Switzerland, as one of the first industrial
manufacturers of branded medicines, Roche has grown into the world’s largest
biotechnology company and the global leader in in-vitro diagnostics. The
company pursues scientific excellence to discover and develop medicines and
diagnostics for improving and saving the lives of people around the world. We
are a pioneer in personalised healthcare and want to further transform how
healthcare is delivered to have an even greater impact. To provide the best
care for each person we partner with many stakeholders and combine our
strengths in Diagnostics and Pharma with data insights from the clinical
practice.

For over 125 years, sustainability has been an integral part of Roche’s
business. As a science-driven company, our greatest contribution to society is
 developing innovative medicines and diagnostics that help people live
healthier lives. Roche is committed to the Science Based Targets initiative
and the Sustainable Markets Initiative to achieve net zero by 2045.

Genentech, in the United States, is a wholly owned member of the Roche Group.
Roche is the majority shareholder in Chugai Pharmaceutical, Japan.

For more information, please visit www.roche.com.

心得/評論：



作為此次投資的一部分，羅氏將擴大其在美國八個州24個地點、超過25,000
名員工的現有規模。

投資內容包括：
在肯塔基州、印第安納州、新澤西州、俄勒岡州和加利福尼亞州擴展和升級
其創新藥物和診斷產品組合的製造和分銷能力

在賓夕法尼亞州建立一座先進的基因療法製造設施

建立一個90萬平方英尺的新製造中心，以支持羅氏不斷擴展的下一代減重藥
物產品組合（地點待公布）

在印第安納州建立一座用於連續血糖監測的新製造設施

在馬薩諸塞州建立一個新的研發中心，進行尖端人工智能（AI）研究，並作
為心血管、腎臟和代謝研究與開發的新中心

在亞利桑那州、印第安納州和加利福尼亞州顯著擴展和升級現有的製藥和診
斷研發中心



一旦所有新建和擴建的製造能力上線，羅氏從美國出口的藥物將超過其進口量
。目前，其診斷部門已從美國向其他國家實現出口順差。

***
丸子
川普一定又要臭彈了
他又要說他的關稅政策又成功了
又一家跨國先進的大公司要到美國投資了

--
--
※ 發信站: 批踢踢實業坊(ptt.cc), 來自: 150.117.197.145 (臺灣)
※ 作者: TyuzuChou 2025-04-22 13:46:27
※ 文章代碼(AID): #1e1oqwyF (Stock)
※ 文章網址: https://www.ptt.cc/bbs/Stock/M.1745300794.A.F0F.html